ASIC accuses ASX company of misleading COVID-19 claims

The chief executive of the WA business allegedly said on a YouTube video that its sanitiser spray can kill the coronavirus, but this had not been tested.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An ASX-listed company, together with its chief executive, has been accused of spruiking false COVID-killing claims about its products.

The Australian Securities and Investments Commission (ASIC) is suing Holista Colltech Limited (ASX: HCT) and its executive chair Dr Rajendran Marnickavasagar, seeking penalties and declarations from the Federal Court.

The corporate watchdog is also advocating for Marnickavasagar to be banned from managing corporations.

Holista shares are currently in a trading halt, pending a response from the Western Australian company.

The stock last traded for 6.6 cents, giving Holista a market capitalisation of around $18 million.

asx share penalty represented by lots of fingers pointing at disgraced businessman Crown royal commission WA

Image source: Getty Images

The accusations against Holista

Marnickavasagar allegedly stated in a YouTube video in February 2020 that Holista's NatShield sanitiser spray killed the coronavirus "involved in the current Wuhan outbreak".

ASIC is claiming this was misleading as the product had not been tested against COVID-19 at the time.

Holista also announced to the ASX on 9 April 2020 that 415,000 bottles of NatShield were purchased by a business named Health Therapies. 

ASIC alleges this $3.8 million order had not been placed at the time.

The ASX company then disclosed to the market on 9 July 2020 that the Health Therapies deal would not be met, and its total revenue for the financial year was back down to just $500,000.

In another ASX announcement in February 2020, Holista claimed it had executed a binding term sheet with another business to collaborate on a new sanitising nasal balm product.

This disclosure is also alleged to be false, as ASIC claims the deal was actually executed 2 months later.

ASIC deputy chair Sarah Court said her organisation is continuing to focus on misleading claims about COVID-19.

"In this case, we are concerned by the allegedly misleading claims, made when there were concerns about a potential pandemic, that NatShield was effective against the virus later known as COVID-19 when it had not been tested against that virus."

The corporate regulator is accusing Holista of violations of the Corporations Act in its civil proceedings.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman's hair is blown back and her face is in shock at this big news.
Healthcare Shares

Why has this ASX biotech fallen nearly 50% today?

A knockback for a key approval has rocked this company.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

Expert names 2 beaten-down ASX All Ords healthcare shares to buy today

A leading analyst expects these two beaten-down ASX healthcare stocks are primed for a rebound.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

7 ASX healthcare stock picks from Bell Potter

Some of these companies are tipped to double in value.

Read more »

Hands reaching high for a trophy with a sunset in the background.
Healthcare Shares

A rare buying opportunity in 1 of Australia's top shares?

This business is generating very healthy profit growth.

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

$10,000 invested in CSL shares in June is now worth…

After plunging to a nine-year low in June, CSL shares have gone gangbusters.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Forget CSL shares. 3 ASX healthcare stocks with bigger upside

Brokers see better opportunities beyond CSL shares.

Read more »

Two scientists analysing results on a computer screen.
Healthcare Shares

3 ASX healthcare shares to buy with 25% to 100% upside as sector rebound races higher

After slumping to a 9-year low on 3 June, healthcare shares have rallied by an extraordinary 42%.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Are CSL shares still cheap after almost doubling since June?

The healthcare giant is no longer dirt cheap, but let's find out if the current valuation leaves room for long-term…

Read more »